{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-023229","form_type":"8-K","ticker":"XTNT","cik":"0001453593","company_name":"Xtant Medical Holdings, Inc.","filed_at":"2023-07-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.981147+00:00","generated_at":"2026-06-13T13:12:09.442549+00:00","sec_items":["1.01","2.02","3.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Xtant Medical raises $15M via private placement of 20M shares at $0.75/share; provides Q2 2023 guidance","bullets":["Private placement of 20M shares at $0.75/share for gross proceeds of $15M.","Expected close on or about July 6, 2023; proceeds for working capital and general corporate purposes.","Investor presentation furnished as Exhibit 99.1 includes financial guidance for Q2 2023 (specifics not in filing).","Craig-Hallum Capital Group is acting as sole placement agent.","Directors and officers executed lock-up agreements; company to file resale registration statement within 30 days."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-023229","json":"https://secwatch.observer/filing/0001493152-23-023229.json","markdown":"https://secwatch.observer/filing/0001493152-23-023229.md","text":"https://secwatch.observer/filing/0001493152-23-023229.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223023229/0001493152-23-023229-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223023229/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T13:12:09.442549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c9f143017fd98a46bfeaa8775cfb20474519b82b","claim":"Xtant Medical Holdings, Inc. updated its the quarter ended June 30, 2023 guidance (initiated).","evidence_excerpt":"On July 3, 2023, the Company made available an investor presentation (the “Investor Presentation”), which contains certain financial guidance, including for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223023229/0001493152-23-023229-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"0e572ae5abfadc64cf7cac8dd2ce80a79d8dab62","claim":"Xtant Medical Holdings, Inc. entered into Placement Agent Agreement with Craig-Hallum Capital Group LLC.","evidence_excerpt":"the Company entered into an engagement letter with Craig-Hallum Capital Group LLC (the “Placement Agent”) pursuant to which the Placement Agent is serving as the Company’s placement agent in connection with the Private Placement (the “Placement Agent Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223023229/0001493152-23-023229-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Craig-Hallum Capital Group LLC"}],"fact_type":"material_agreement"},{"claim_id":"aa582f16288b78f92b4aa88172776c12861b926c","claim":"Xtant Medical Holdings, Inc. entered into Securities Purchase Agreement with accredited investors (the \"Investors\") valued at $15.0 million (effective 2023-07-03).","evidence_excerpt":"On July 3, 2023, Xtant Medical Holdings, Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with accredited investors (the “Investors”), pursuant to which the Company agreed to issue an aggregate of 20,000,000 shares (the “Shares”) of common stock, par value $0.000001 per share (the “Common Stock”), in a private placement (the “Private Placement”), at a per Share purchase price of $0.75.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1453593/000149315223023229/0001493152-23-023229-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"accredited investors (the \"Investors\")"},{"label":"Value","value":"$15.0 million"},{"label":"Effective","value":"2023-07-03"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}